Introduction

Batten Disease is a genetic disorder which is caused by autosomal recessive genetic mutation mainly occur in the childhood. Batten disease is also considered as lysosome shortage disease.

Symptom of batten diseases occur due to malfunctioning of the body and can be observed between the age of five and fifteen years but it takes a few years to show symptoms such as vision loss, behaviors changes resulting in blindness and Parkinson-like symptoms. FDA approve first cerliponase alfa first ever drug to treat a slow loss of walking ability.

Till, there is no treatment but there are few tests for batten disease and can be diagnosed by some laboratory tests which include blood test, urine sample MRI and CT scan. According to the National Human Genome Research Institute (NHGRI), Juvenile batten is one of the common diseases affecting almost 30 million population.

There are some clinical trials studies being carried out in the North America, Western Europe, and Asia Pacific which is expected to increase the demand for batten disease treatment.

Increased prevalence of disease and clinical trials are expected to spur the growth of batten disease treatment market. A number of physical therapies may be used to treat the batten disease such as stem-cell therapy, enzyme-replacement therapy and gene therapy are expected to increase the demand for batten disease treatment.

In addition, there is also fetal stem cell material which may be possible to treat brain of affected children and this is anticipated to increase the growth of batten disease treatment market. Besides, receiving vitamin supplements also help affected children and resulted slowing of the batten disease which is expected to increase the growth of batten disease treatment market.

However, factors such as no specific treatment for batten disease treatment will hinder the growth of batten disease treatment market.